NCT05629429 - Olaparib Maintenance Therapy in Metastatic Breast Cancer | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Olaparib

Olaparib 300mg BID PO

DRUG

Chemotherapy drug

Continue platinum based chemotherapy

Trial Locations (3)

RECRUITING

National Taiwan University Hospital, Taipei

NOT_YET_RECRUITING

Taipei Veterans General Hospital, Taipei

NOT_YET_RECRUITING

National Taiwan University Hospital Yunlin branch, Yuanlin